A miraculous drug, crafted from the blood of dedicated scientists, has emerged as a life-saving antidote for infants battling botulism. This rare treatment, known as BabyBIG, has become a beacon of hope for parents facing the terrifying prospect of this potentially deadly disease.
When Alessandro Barbera's life hung in the balance, his father, Tony, was unaware of the disease's existence, let alone the extraordinary treatment that would prove pivotal. Now, Tony expresses profound gratitude for BabyBIG, the sole remedy for the paralyzing effects of botulism linked to contaminated infant formula.
"It's nothing short of remarkable," says Tony, whose son is on the path to recovery. The botulism outbreak associated with ByHeart formula has impacted at least 39 infants across 18 US states since August, highlighting the critical role of this treatment derived from the plasma of a dedicated group of donors.
Dr. Vijay Viswanath, a pediatric neurologist at Children's Hospital Los Angeles, describes BabyBIG as a "miracle.
"Prior to BabyBIG, hospitalizations for botulism could stretch for months, with uncertain outcomes," he explains. Licensed in 2003, BabyBIG, or human botulism immune globulin, is an IV medication that harnesses the power of antibodies from vaccinated volunteers to bolster the immune systems of infants too young to fight the disease independently.
The treatment's development is a testament to the vision of the late Dr. Stephen Arnon, a scientist with the California Department of Public Health. Arnon and his colleagues identified the rare form of botulism affecting infants under one year old in 1976 and dedicated his career to finding a treatment.
Botulism occurs when babies ingest spores that germinate in the intestine, producing a toxin that attacks the nervous system. Since Arnon's team conducted a pivotal clinical trial in California in 1997, over 3,700 children worldwide have been treated with BabyBIG, demonstrating its ability to reduce hospital stays and the need for breathing support.
Produced in small batches every five years, BabyBIG carries a price tag of nearly $70,000 per treatment, according to the California Infant Botulism Treatment and Prevention Program, founded by Arnon. The program's funding comes solely from the sale of the drug, ensuring its sustainability.
The treatment relies on donors like Nancy Shine, a retired 76-year-old biochemist from California. Shine was vaccinated against botulism due to her work with the germ in a lab, and her blood's high antibody levels made her an ideal candidate for the BabyBIG project.
"It wasn't a pleasant experience being vaccinated," Shine recalls. "There were side effects, like large welts and some pain." Despite this, Shine has contributed to three batches of the antitoxin produced between 2008 and 2019, a testament to her commitment.
"It's the highlight of my career to be part of this project and donate plasma," she says. "We created a product that saves infants' lives."
The development of BabyBIG faced significant challenges due to the rarity of infant botulism, with fewer than 200 cases reported in the US annually. It took nearly 15 years and $10.6 million to bring the treatment to fruition, and Arnon noted substantial hurdles in a 2007 article.
Today, about 30 people donate plasma for each batch of BabyBIG, and the latest edition, Batch 8, is being manufactured at a Takeda Pharmaceutical Co. plant near Los Angeles. The company produces BabyBIG on a "not-for-profit" basis, ensuring its accessibility.
Some of the earliest donors, like Shine, have aged out of the program, which accepts volunteers up to age 70. New donors must enroll in a clinical study directed by the California health department and receive a booster dose of an investigational botulism vaccine.
California officials estimate they have sufficient reserves of BabyBIG to last until next summer, based on current projections. However, the ByHeart outbreak is part of a broader concern, with at least 107 infant botulism cases treated in the US since August, according to Dr. Jessica Khouri, senior medical officer for the state program.
Shine recently received a booklet filled with photos and letters from families whose children have recovered from botulism thanks to BabyBIG. "It's really wonderful. I read a couple each day," she says. "Every single one makes you want to cry."
And this is the part most people miss: the incredible dedication and sacrifice of these donors, who, through their blood, offer a second chance at life for these infants. It's a powerful reminder of the impact we can have on others, even in the face of rare and challenging diseases.
